Evidence map›Paper›PMID 40137493›Full record

ArticleToxics2025

Lentinan Alleviated PM2.5 Exposure-Induced Epithelial-Mesenchymal Transition in Pulmonary Epithelial Cells by Inhibiting the GARP/TGF-β/Smad Pathway.

Zhi Wang, Shiqing Xu, Bohao Bian, Zhida Hu, Feiyang Wu, Siqi Zhao, Xiaohui Wang, Li Wang, Teng Ma

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Toxics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Zhi WangSchool of Public Health, Baotou Medical College, Inner Mongolia University of Science & Technology, Baotou 014040, China.
Shiqing XuSchool of Public Health, Baotou Medical College, Inner Mongolia University of Science & Technology, Baotou 014040, China.
Bohao BianHulunbuir Center for Disease Control and Prevention, Hulun Buir 021000, China.
Zhida HuCangzhou People's Hospital, Department of Hospital Infection Management, Cangzhou 061000, China.
Feiyang WuSchool of Public Health, Baotou Medical College, Inner Mongolia University of Science & Technology, Baotou 014040, China.
Siqi ZhaoSchool of Public Health, Baotou Medical College, Inner Mongolia University of Science & Technology, Baotou 014040, China.
Xiaohui WangSchool of Public Health, Baotou Medical College, Inner Mongolia University of Science & Technology, Baotou 014040, China.
Li WangSchool of Public Health, Baotou Medical College, Inner Mongolia University of Science & Technology, Baotou 014040, China.
Teng MaSchool of Public Health, Baotou Medical College, Inner Mongolia University of Science & Technology, Baotou 014040, China.

Funding

Natural Science Foundation Project of Inner Mongolia Autonomous Region 2022QN08019
6 · The paper itself

Abstract

PM2.5 (fine particulate matter) is an air pollutant widely present in urban and industrial areas, which has emerged as a significant threat to human health. Specifically, long-term exposure to PM2.5 could lead to various lung diseases, including pulmonary fibrosis and Chronic Obstructive Pulmonary Disease (COPD). The Glycoprotein A Repetitions Predominant (GARP) protein, a key receptor and regulator for TGF-β1, has recently emerged as a vital cytokine in PM2.5-induced pulmonary pathological changes. As a membrane glycoprotein, GARP binds to TGF-β, keeping it in an active state. Herein, PM2.5 treatment upregulated GARP and promoted Epithelial-Mesenchymal Transition (EMT) via TGF-β/SMAD signaling pathway activation. Conversely, lentinan (a shiitake mushroom-derived polysaccharide) effectively reversed the PM2.5-induced GARP upregulation, alleviating EMT. This study elucidates the role of GARP in PM2.5-induced EMT through the TGF-β/SMAD pathway in pulmonary epithelial cells and discusses the therapeutic potential of lentinan.

Indexed as

COPDEMTGARPlentinanPM2.5

Identifiers

PMID40137493
PMCPMC11946725

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.